Lenalidomide and Dexamethasone (LEN plus DEX) Treatment in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) and Risk of Second Primary Malignancies.

Slides:

Advertisements

Similar presentations

Miles DW et al. SABCS 2009;Abstract 41.

Advertisements

Verstovsek S et al. Proc ASCO 2011;Abstract 6500.

Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study Garcia-Manero G et al. Proc ASH 2010;Abstract 603.

Phase I/II Trial of the MEK1/2 Inhibitor GSK (GSK212) in Patients with Relapsed/ Refractory Myeloid Malignancies: Evidence of Activity in Pts with.

Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas Illidge T et al. Proc ASH 2011;Abstract.

Survival Analysis In many medical studies, the primary endpoint is time until an event occurs (e.g. death, remission) Data are typically subject to censoring.

ROCKET-AF Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial.

ACRIN Abdominal Committee ACRIN Gynecologic Committee Fall Meeting 2010.

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Bendamustine + Rituximab (BR) Chemoimmunotherapy and Maintenance Lenalidomide in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small.

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk.

UK Renal Registry 17th Annual Report Figure 5.1. Trend in one year after 90 day incident patient survival by first modality, 2003–2012 cohorts (adjusted.

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.

Palumbo A et al. Proc ASH 2013;Abstract 536.

Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously.

Facon T et al. Proc ASH 2013;Abstract 2.

1. 2 Lenalidomide in Newly Diagnosed Multiple Myeloma Clinical Update EHA 2010 DR. OUSSAMA JRADI.

Richardson PG et al. Proc ASH 2013;Abstract 535.

Palumbo A et al. Proc ASH 2012;Abstract 446.

1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.

Relapsed and Refractory Myeloma Case 2

Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.

Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated.

Lenalidomide Maintenance Therapy in Multiple Myeloma: A Meta-Analysis of Randomized Trials Singh PP et al. Proc ASH 2013;Abstract 407.

Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients Palumbo A.

Maintenance Therapy in Myeloma Myeloma Canada National Conference Donna E. Reece, M.D. Princess Margaret Hospital 24 September 2011.

Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.

Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) 1 Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study.

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin plus Cytarabine versus Placebo plus.

Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance.

OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Lonial.

Long Term Follow-up on the Treatment of High Risk Smoldering Myeloma with Lenalidomide plus Low Dose Dex (Rd) (Phase III Spanish Trial): Persistent Benefit.

ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Mark TM et al. Proc ASH 2012;Abstract 77.

A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.

Continued Overall Survival Benefit After 5 Years’ Follow-Up with Bortezomib-Melphalan-Prednisone (VMP) versus Melphalan-Prednisone (MP) in Patients with.

A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Shah.

Second Interim Analysis of a Phase 3 Study of Idelalisib Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient.

Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.

Moskowitz CH et al. Proc ASH 2014;Abstract 673.

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed or Refractory.

MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,

Pomalidomide + Low-Dose Dexamethasone (POM + LoDex) vs High-Dose Dexamethasone (HiDex) in Relapsed/Refractory Multiple Myeloma (RRMM): MM-003 Analysis.

CCO Independent Conference Highlights

Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)

ELOQUENT-2: Elotuzumab + Len/Dex in R/R MM

Attal M et al. Proc ASH 2010;Abstract 310.

Pomalidomide Plus Low-Dose Dex vs High-Dose Dex in Rel/Ref Myeloma

Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple.

Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al

Multiple Myeloma in Session 2015: An Online Journal Club for Hematology/Oncology Fellows This program is supported by educational grants from Celgene Corporation.

Elotuzumab, Lenalidomide, and Low-Dose Dexamethasone in Relapsed/Refractory Myeloma Slideset on: Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination.

San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.

Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.

Attal M et al. Proc ASCO 2010;Abstract 8018.

Background and update from Myeloma XI Dr John Jones

Rossi A et al. Proc ASCO 2011;Abstract 8008.

Palumbo A et al. Proc ASCO 2011;Abstract 8007.

Vesole DH et al. Proc ASH 2010;Abstract 308.

Baselga J et al. SABCS 2009;Abstract 45.

Faderl S et al. Proc ASCO 2011;Abstract 6503.

Zaja F et al. Proc ASH 2010;Abstract 966.

Pomalidomide plus Low-Dose Dexamethasone in Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies in Dual-Refractory.

Boccadoro M et al. Proc ASCO 2011;Abstract 8020.

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

Malignancy-related events over time for all-bari-RA analysis set (IR).

Maintenance therapies in Multiple Myeloma

Presentation transcript:

Lenalidomide and Dexamethasone (LEN plus DEX) Treatment in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) and Risk of Second Primary Malignancies (SPM): Analysis of MM-009/010 Dimopoulos MA et al. Proc ASCO 2011;Abstract 8009.

MM-009/010 Study Designs Analysis of pooled data from patients with relapsed/refractory multiple myeloma (RRMM) treated in 2 Phase III studies (MM-009) and (MM-010): N = 704 R LEN 25 mg/d d1-21 Dex: 40 mg/d d1-4, 9-12, st 4 cycles; 40 mg/d d1-4 subsequent cycles Placebo d1-28 Dex: 40 mg/d d1-4, 9-12, st 4 cycles; 40 mg/d d1-4 subsequent cycles Continue until disease progression Dimopoulos MA et al. Proc ASCO 2011;Abstract 8009.

Incidence Rates for SPM During Active Treatment Phase (Safety Population) LEN + DEX (N = 353)PBO + DEX (N = 350) SPM n (%) Incidence (per 100 PY)n (%) Incidence (per 100 PY) Invasive SPM 8 (2.3%)1.712 (0.6%)0.91 Hematologic2 (0.6%)0.420 (0%)0.00 AML/MDS2 (0.6%)0.420 (0%)0.00 B-cell malignancies0 (0%)0.000 (0%)0.00 Solid tumors6 (1.7%)1.282 (0.6%)0.91 Noninvasive SPM11 (3.1%)2.402 (0.6%)0.91 Nonmelanoma skin cancer 11 (3.1%)2 (0.6%) TOTAL SPM18 (5.1%)*3.983 (0.9%)*1.38 * Pts with >1 SPM counted once in the total Dimopoulos MA et al. Proc ASCO 2011;Abstract 8009.

* Includes MDS and breast carcinoma in situ; excludes nonmelanoma skin cancers PBO + Dex (n = 350) Len + Dex (n = 353) Double-blind phaseLong-term follow-up only SPM = 2 IR: 1.91 (95% CI ) IR: 0 IR: 1.71 (95% CI ) IR: 0 SPM = 0 SPM = PY total 886 PY total 599 PY218 PY 467 PY419 PY Person-Years Incidence Rates of Invasive SPM* During Treatment and Follow-Up With permission from Dimopoulos MA et al. Proc ASCO 2011;Abstract 8009.

Time (months) Patients (%) Len + Dex PBO + Dex Hazard ratio: (95% CI ) p = No. at RiskTime (months) Len + Dex PBO + Dex SPM in RRMM: MM-009/010 Time to Invasive SPM (Treatment Period) With permission from Dimopoulos MA et al. Proc ASCO 2011;Abstract 8009.

LEN + DEX in RRMM: Overall Survival (Up to Unblinding) TreatmentMedian OSp-value Len + Dex31 months <0.001 PBO + Dex24 months Hazard ratio: (95% CI ) Overall Survival (months) Patients (%) Logrankp < Wilcoxonp < Pepe-Flemingp = With permission from Dimopoulos MA et al. Proc ASCO 2011;Abstract 8009.

LEN + DEX Overall Survival Including Data After Crossover TreatmentMedian OSp-value Len + Dex38.0 months PBO + Dex31.6 months Hazard ratio: (95% CI ) Overall Survival (months) Patients (%) Logrankp = Wilcoxonp = Pepe-Flemingp = With permission from Dimopoulos MA et al. Proc ASCO 2011;Abstract 8009.

Conclusions No difference in incidence rates of invasive SPMs in LEN + DEX arm versus PBO + DEX in MM-009/010 SPM incidence rates were low and similar to the background incidence among persons similarly aged in the general population OS was significantly longer for patients who received LEN + DEX –Confirmed with long-term follow-up despite ~50% of patients in the PBO + DEX arm crossing over to receive LEN-based therapy The overall benefit-risk profile of LEN in RRMM remains strongly positive Dimopoulos MA et al. Proc ASCO 2011;Abstract 8009.

Investigator Commentary: The Incidence of SPMs After Long-Term Follow-Up of MM-009/010 in RRMM Dr Niesvizky presented long-term follow-up of MM-009/010, which were the pivotal studies for approval of lenalidomide in relapsed/refractory multiple myeloma. The incidence of observed versus expected cancer was relatively similar, and many of these patients had already received high- dose melphalan and other treatments. So in this population there did not seem to be an increased risk of SPMs. Lenalidomide has stem cell activity, and it is plausible that it can affect stem cells to a point that there may be development of SPMs, but it doesn’t seem to be a common phenomenon. When SPMs develop after lenalidomide, it happens after prolonged alkylator therapy or after high- dose alkylating agent exposure, such as in the transplant setting. I initiate lenalidomide maintenance therapy for any patient who has not achieved a complete remission or in patients who have a high risk for relapse, even if they have achieved a CR. I delay lenalidomide maintenance for 5 to 6 months after transplant because I believe the “perfect storm ” is to administer a drug that may be stem cell toxic at a time when the stem cells are beginning to proliferate and find their essential microenvironments. Sergio Giralt, MD